---
pmid: '19727662'
title: Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in
  human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase
  activity.
authors:
- Romacho T
- Azcutia V
- Vázquez-Bella M
- Matesanz N
- Cercas E
- Nevado J
- Carraro R
- Rodríguez-Mañas L
- Sánchez-Ferrer CF
- Peiró C
journal: Diabetologia
year: '2009'
full_text_available: false
doi: 10.1007/s00125-009-1509-2
---

# Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity.
**Authors:** Romacho T, Azcutia V, Vázquez-Bella M, Matesanz N, Cercas E, Nevado J, Carraro R, Rodríguez-Mañas L, Sánchez-Ferrer CF, Peiró C
**Journal:** Diabetologia (2009)
**DOI:** [10.1007/s00125-009-1509-2](https://doi.org/10.1007/s00125-009-1509-2)

## Abstract

1. Diabetologia. 2009 Nov;52(11):2455-2463. doi: 10.1007/s00125-009-1509-2. Epub 
2009 Aug 29.

Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human 
vascular smooth muscle cells through nicotinamide phosphoribosyltransferase 
activity.

Romacho T(1), Azcutia V(1), Vázquez-Bella M(1), Matesanz N(1), Cercas E(1), 
Nevado J(2), Carraro R(3), Rodríguez-Mañas L(4), Sánchez-Ferrer CF(1), Peiró 
C(5).

Author information:
(1)Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad 
Autónoma de Madrid, Arzobispo Morcillo, 4, 28029, Madrid, Spain.
(2)Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La 
Paz, Madrid, Spain.
(3)Servicio de Endocrinología, Hospital Universitario de La Princesa y 
Universidad Autónoma de Madrid, Madrid, Spain.
(4)Unidad de Investigación y Servicio de Geriatría, Hospital Universitario de 
Getafe, Getafe, Spain.
(5)Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad 
Autónoma de Madrid, Arzobispo Morcillo, 4, 28029, Madrid, Spain. 
concha.peiro@uam.es.

AIMS/HYPOTHESIS: Extracellular pre-B cell colony-enhancing factor/nicotinamide 
phosphoribosyltransferase/visfatin (ePBEF/NAMPT/visfatin) is an adipocytokine, 
whose circulating levels are enhanced in metabolic disorders, such as diabetes 
mellitus and obesity. Here, we explored the ability of ePBEF/NAMPT/visfatin to 
promote vascular inflammation, as a condition closely related to 
atherothrombotic diseases. We specifically studied the ability of 
PBEF/NAMPT/visfatin to directly activate pathways leading to inducible nitric 
oxide synthase (iNOS) induction in cultured human aortic smooth muscle cells, as 
well as the mechanisms involved.
METHODS: iNOS levels and extracellular signal-regulated kinase (ERK) 1/2 
activity were determined by western blotting. Nuclear factor (NF)-kappaB 
activity was assessed by electrophoretic mobility shift assay.
RESULTS: ePBEF/NAMPT/visfatin (10-250 ng/ml) induced iNOS in a 
concentration-dependent manner. At a submaximal concentration (100 ng/ml), 
ePBEF/NAMPT/visfatin time-dependently enhanced iNOS levels up to 18 h after 
stimulation. Over this time period, ePBEF/NAMPT/visfatin elicited a sustained 
activation of NF-kappaB and triggered a biphasic ERK 1/2 activation. By using 
the respective ERK 1/2 and NF-kappaB inhibitors, PD98059 and pyrrolidine 
dithiocarbamate, we established that iNOS induction by ePBEF/NAMPT/visfatin 
required the consecutive upstream activation of ERK 1/2 and NF-kappaB. The 
pro-inflammatory action of ePBEF/NAMPT/visfatin was not prevented by insulin 
receptor blockade. However, exogenous nicotinamide mononucleotide, the product 
of NAMPT activity, mimicked NF-kappaB activation and iNOS induction by 
ePBEF/NAMPT/visfatin, while the NAMPT inhibitor APO866 prevented the effects of 
ePBEF/NAMPT/visfatin on iNOS and NF-kappaB.
CONCLUSIONS/INTERPRETATION: Through its intrinsic NAMPT activity, 
ePBEF/NAMPT/visfatin appears to be a direct contributor to vascular 
inflammation, a key feature of atherothrombotic diseases linked to metabolic 
disorders.

DOI: 10.1007/s00125-009-1509-2
PMID: 19727662 [Indexed for MEDLINE]
